AbbVie Inc (ABBV)

ABBV (NYSE:Drugs) EQUITY
$69.95
pos +0.22
+0.32%
Today's Range: 69.67 - 70.39 | ABBV Avg Daily Volume: 9,570,300
Last Update: 08/04/15 - 4:02 PM EDT
Volume: 5,395,159
YTD Performance: 6.56%
Open: $70.04
Previous Close: $69.73
52 Week Range: $51.37 - $71.60
Oustanding Shares: 1,593,076,097
Market Cap: 111,531,257,551
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 9 8 8
Moderate Buy 0 0 0 0
Hold 2 2 2 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.33 1.36 1.40 1.22
Latest Dividend: 0.51
Latest Dividend Yield: 2.91%
Dividend Ex-Date: 07/13/15
Price Earnings Ratio: 43.76
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
43.76 54.60 25.65
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
8.41% 32.87% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue 6.20 0.14 0.05
Net Income -57.00 -0.48 -0.20
EPS -57.20 0.00 0.00
Earnings for ABBV:
EBITDA 4.95B
Revenue 19.96B
Average Earnings Estimates
Qtr (09/15) Qtr (12/15) FY (12/15) FY (12/16)
Average Estimate $1.07 $1.19 $4.27 $5.06
Number of Analysts 8 6 10 10
High Estimate $1.09 $1.21 $4.30 $5.43
Low Estimate $1.02 $1.15 $4.20 $4.75
Prior Year $0.89 $0.89 $3.32 $4.27
Growth Rate (Year over Year) 20.22% 33.15% 28.46% 18.71%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

David Katz

 | Jul 30, 2015 | 11:00 AM EDT

Drugmaker has one of the best showings of earnings season.

By

David Katz

 | Jul 30, 2015 | 8:30 AM EDT

Drugmaker has one of the best showings of earnings season.

By

Chris Laudani

 | Jul 28, 2015 | 8:00 AM EDT

Competition and lower earnings cloud its future.

bullishAbbvie estimates, target increased at BMO

Jul 21, 2015 | 7:42 AM EDT

ABBV estimates were raised through 2016, BMO Capital said. Company should see higher Hepatitis C sales and is cutting costs. Outperform rating and new $77 price target. 

By

Jim Cramer

 | Jul 20, 2015 | 7:33 AM EDT

Don't make a learning week a gambling week.

By

Jim Cramer

 | Jul 15, 2015 | 7:07 AM EDT

These stocks will be up so high today, that many fans will say "no thanks."

By

Jim Cramer

 | Jul 13, 2015 | 6:13 AM EDT

This market is almost entirely special situation.

By

David Peltier

 | Jul 10, 2015 | 11:00 AM EDT

Duke Energy's recent increase puts its payout at the high end of the industry range.

By

Chris Laudani

 | Jun 24, 2015 | 1:00 PM EDT

The biotech's stock has likely peaked, as increased competition awaits in the Hep-C space.

By

Jim Cramer

 | Jun 11, 2015 | 2:18 PM EDT

New companies are coming up with major drugs.

The company reports revenues of $171.3 million versus expectations of $168.6 million. Sh...
IBM is extending its nasty July 21st(earnings)breakdown today. The stock is drifting ...
The Nasdaq Trade Reporting Facility malfunctioned this morning. That caused several dark ...
Market is flat as we approach midday which is not bad performance given the continued sell...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.